Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$112.23 USD

112.23
3,472,141

-1.41 (-1.24%)

Updated Oct 3, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott (ABT) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Abbott (ABT) concluded the recent trading session at $113.64, signifying a +0.07% move from its prior day's close.

Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $112.73, moving +0.11% from the previous trading session.

Here's Why Abbott (ABT) Fell More Than Broader Market

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $113.70, moving -0.39% from the previous trading session.

Abbott Stock Hurt by Macroeconomic Issues & FX Headwind

by Zacks Equity Research

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.

PAHC vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

PAHC vs. ABT: Which Stock Is the Better Value Option?

Abbott (ABT) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Abbott (ABT) reachead $117.63 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.

High Tide Inc. (HITI) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

High Tide (HITI) delivered earnings and revenue surprises of 150% and 2.50%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe

by Zacks Equity Research

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.

Urmimala Biswas headshot

Medtronic Keeps Capturing High-Growth Markets: Time to Buy MDT Stock?

by Urmimala Biswas

MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.

Why Abbott (ABT) Outpaced the Stock Market Today

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $117.11, marking a +0.58% move from the previous day.

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?

by Zacks Equity Research

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.

Debanjana Dey headshot

Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?

by Debanjana Dey

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

by Zacks Equity Research

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Should You Continue to Retain ABT Stock in Your Portfolio Now?

by Zacks Equity Research

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $114.66, marking a +1.23% move from the previous day.

PAHC vs. ABT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PAHC vs. ABT: Which Stock Is the Better Value Option?

Abbott (ABT) Stock Moves -0.18%: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $112.90, moving -0.18% from the previous trading session.

ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition

by Zacks Equity Research

Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.

DexCom Stock May Gain on Expanded Reach After Stelo's US Launch

by Zacks Equity Research

DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.